CytoSorbents Corporation filed a Form 8-K on September 23, 2026, disclosing that it has regained compliance with Nasdaq's minimum bid price requirement while remaining out of compliance with the market value of listed securities requirement, with a deadline of December 28, 2026, to resolve the latter.

Key Highlights

  • Bid Price Compliance Restored: On September 22, 2026, Nasdaq's Listing Qualifications Staff confirmed CytoSorbents has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement of $1.00 per share, and the matter is closed.
  • MVLS Deficiency Remains: The company received a notice on June 29, 2026, that its market value of listed securities was below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2).
  • Compliance Deadline: Nasdaq provided 180 calendar days, or until December 28, 2026, for the company to regain compliance with the MVLS Requirement.
  • Compliance Threshold: To regain compliance, the market value of listed securities must equal or exceed $35 million for a minimum of 10 consecutive business days during the compliance period.
  • Alternative Path: The company disclosed it may consider increasing stockholders' equity to at least $2.5 million as another option to regain compliance.
  • Delisting Risk: If compliance is not regained by December 28, 2026, the company stated it will receive written notification that its securities are subject to delisting, at which time it may appeal.

CytoSorbents Navigates Two Separate Nasdaq Listing Compliance Matters

According to the filing, CytoSorbents Corporation (NASDAQ:CTSO) addressed two distinct Nasdaq listing compliance issues in its September 23, 2026 Form 8-K. The first matter, originally triggered by a letter from Nasdaq's Listing Qualifications Staff on October 2, 2025, concerned the company's failure to meet Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The filing confirmed that on September 22, 2026, the Staff notified the company that it has regained compliance and "the matter is now closed."

The second matter remains open. The filing disclosed that on June 29, 2026, the company received written notice of non-compliance with Nasdaq Listing Rule 5550(b)(2) because the market value of its listed securities fell below the $35 million minimum. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the company was granted 180 calendar days, until December 28, 2026, to regain compliance. The filing noted that Nasdaq retains discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H).

The company disclosed it "is evaluating potential actions to regain compliance with the MVLS Requirement and intends to continue to monitor the market value of its listed securities." The filing also stated the company may consider increasing stockholders' equity to at least $2.5 million as an alternative path. The company cautioned: "There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain the listing of its common stock on the Nasdaq Capital Market." The filing was signed by Dr. Phillip P. Chan, Chief Executive Officer.

What Was Disclosed

CytoSorbents disclosed in an 8-K that it resolved a prior Nasdaq minimum bid price deficiency while a separate market value of listed securities deficiency, received June 29, 2026, remains outstanding with a December 28, 2026 deadline to regain compliance.